Clinical Trial Update: SYN-004 Safety and Tolerability in Allo-HCT Subjects [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial evaluating safety and tolerability of SYN-004 in adults undergoing allogeneic hematopoietic stem cell transplantation, including preventio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection
• Graft-versus-host Disease

Drugs mentioned

• SYN-004

Snippet

Sponsor: Theriva Biologics, Inc. | Conditions: Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING